These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification. Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634 [TBL] [Abstract][Full Text] [Related]
14. Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis. Stanley A; Heo SJ; Mauck RL; Mourkioti F; Shore EM J Bone Miner Res; 2019 Oct; 34(10):1894-1909. PubMed ID: 31107558 [TBL] [Abstract][Full Text] [Related]
15. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva. Cappato S; Giacopelli F; Ravazzolo R; Bocciardi R Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587443 [TBL] [Abstract][Full Text] [Related]
17. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737 [TBL] [Abstract][Full Text] [Related]